Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Most gastric cancers develop on the background of chronic inflammation of the gastric mucosa with glandular atrophy and intestinal metaplasia representing preneoplastic conditions. Infection with Helicobacter pylori is the most relevant risk factor, with dietary factors and host genetic factors further modifying the risk, supporting a central role of the modulation of the local and systemic immune-response in gastric cancer onset. Recent multiomics profiling studies helped to better understand the pathobiological features of the disease, but translation of the new knowledge into clinical practice is slow. Due to a lack of noninvasive biomarkers, gold-standard for diagnosis of gastric cancer is assessment by gastroscopy and respective biopsy sampling. Modern advances in virtual chromoendoscopy facilitate the detection of early neoplastic lesions. Patients with advanced neoplastic conditions should be enrolled in endoscopic surveillance programs with structured gastric cancer screening strategies being currently available only in high incidence countries in Asia.

Original publication

DOI

10.1016/B978-0-12-801238-3.65678-7

Type

Book title

Encyclopedia of Gastroenterology, Second Edition

Publication Date

01/01/2019

Pages

553 - 564